MacuLogix Adds Clinical Advisory Board Members
Leading Optometrists to provide crucial guidance to MacuLogix
HUMMELSTOWN, Pa., October 9, 2014 – MacuLogix®, Inc.,
a pioneer in the early detection and tracking of retinal diseases, announced the appointment of Steven G. Ferrucci, OD, FAAO and Jeffry D. Gerson, OD, FAAO, as Clinical Advisors. Drs. Ferrucci and Gerson will provide guidance on the development and commercialization of the Company’s AdaptDx®, an advanced dark adaptometer used by eye care physicians to assess retinal health and function, and by researchers to support development of new drugs for age-related macular degeneration.
“Dr. Ferrucci and Dr. Gerson each bring unique expertise to our company,” said John G. Edwards, CEO of MacuLogix. “In order to help physicians preserve vision for millions of people around the world, it’s important that MacuLogix has a strong team of experts who can aid in the evolution of our instrument,” he added.
“Understanding AMD is a core area of my work, and I believe the AdaptDx can provide valuable and early insight in AMD,” said Dr. Ferrucci. “I look forward to providing clinical guidance to the company.” Drs. Ferrucci and Gerson will apply their extensive knowledge of retinal disease and patient care to provide insights into macular degeneration and guide the development of the AdaptDx.
Bios – Steven G. Ferrucci, OD, FAAO and Jeffry D. Gerson, OD, FAAO
Steven G. Ferrucci, OD, FAAO
Steven G. Ferrucci is the Chief of Optometry at the Sepulveda VA Hospital in Sepulveda CA and an Associate Professor at the Southern California College of Optometry.
Dr. Ferrucci has lectured extensively with special interest in AMD and diabetic eye disease and has published numerous articles on these subjects. He is an active member in the American Optometric Association and the National VA Optometric Association, as well as a fellow in both the American Academy of Optometry and the Optometric Retinal Society. He also currently serves on the American Optometric Association, Nutrition and Ocular Health Committee. Dr. Ferrucci is a 1994 graduate of the New England College of Optometry. He completed his Residency in Primary Care/Hospital Based/Geriatric Optometry at the Sepulveda VA Hospital.
Jeffry D. Gerson, OD, FAAO
Jeffry D. Gerson is currently in private practice in Kansas City where he provides full-scope patient care, retinal consultation for colleagues, and is involved in clinical research. During his career he has been involved in several practice settings, including a retinal referral center where he gained expertise with many important diagnostic technologies and participated in numerous clinical trials.
Dr. Gerson has authored several articles in journals such as “Review of Optometry” and “Optometric Management”. He lectures frequently on the topics of retinal disease and systemic disease. He is on numerous advisory boards, is a member of the American Optometric Association and the Kansas Optometric Association which named him their 2008 young OD of the year. He is a fellow of both the Academy of Optometry and Optometric Retina Society.
Dr. Gerson graduated from Indiana University School of Optometry in 1997. He then completed a residency at the VA Medical Center in Kansas City concentrating on ocular disease and low vision. After leaving the VA, he became faculty at the University of Kansas School of Medicine in the Department of Ophthalmology.
MacuLogix, Inc. is a pioneer in the early detection and tracking of retinal diseases. The Company’s AdaptDx® is the first practical measurement tool for dark adaptation. Dark adaptation is known to be substantially impaired in degenerative diseases of the macula such as age-related macular degeneration (AMD) and inherited macular dystrophies. Based on significant technical advances, the AdaptDx provides doctors with an easy-to-use functional test for macular degeneration similar to routine perimetry testing for glaucoma.